Selected Start-Ups (12/00)
Executive Summary
In Vivo summarizes the technologies of several recently founded companies: Roche has funneled its IP in antibiotics, antifungals and dermatology into spin-off Basilea Pharmaceutica. Building on technology invented by NASA to detect life on Mars, BioLuminate Inc. will develop a diagnostic probe to measure breast cancer indicators after initial screening has revealed a region of concern. Integrative Proteomics Inc. aims to be a dominant player in proteomics with its platform for high-throughput protein expression and purification, protein-protein interaction and 3-dimensional structure determination. invivodata inc. is offering a money-back guarantee to users of its invivosystem, a handheld method for recording, managing and analyzing real-time patient experience data during pharmaceutical clinical trials. Metazoa Systems Inc. has launched a web portal offering research management tools for life science researchers. Aventis CropScience spin-off Scynexis Chemistry & Automation Inc. will provide drug discovery chemistry services for pharmaceutical and other life sciences clients.
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.